Practical reading from Professor Paul Lee and the Lincolnshire Hip Clinic team — across hip replacement, Arthrosamid, ChondroFiller, PRP and the wider world of hip and groin pain.
SPAIRE hip replacement preserves the posterior stabilising tendons that conventional posterior approaches must cut, eliminating the need for the strict movement restrictions — no bending beyond 90°, no leg crossing — that define recovery from standard hip replacement.
Hip abductor strength below 0.031 kgf·m/kg predicts need for post-operative rehabilitation rather than direct discharge; strength of around 1.0 Nm/kg correlates with better walking ability one year after total hip replacement.
Hip replacement for dysplasia is not the same operation as replacement for ordinary osteoarthritis. The incompletely formed socket leaves the femoral head only partially covered, concentrating stress on a small patch of cartilage; this anatomical difference means revision risk is 1.66 times higher.
ChondroFiller is an injectable collagen scaffold that self-gels in the hip joint and recruits the body's own cells to repair damaged cartilage over three to six months.
In hip dysplasia, shallow or tilted acetabular coverage concentrates load on the superior rim; the labrum compensates by enlarging but eventually tears, driving cartilage damage and osteoarthritis in approximately 20% of symptomatic patients within eight years.
Hip osteoarthritis progression varies greatly: some patients advance from mild to severe within two to three years, while others remain stable for a decade.
ChondroFiller injection—a collagen scaffold—produced 80% good-to-excellent cartilage healing in a 21-patient hip cohort over one to five years by enabling the patient's progenitor cells to migrate into the defect and regenerate cartilage.
HemiSPAIRE preserves the hip's posterior tendons during femoral neck fracture repair, matching the dislocation safety of the lateral approach without the abductor weakness that impairs early mobilisation in elderly patients.
ChondroFiller, injected into focal hip cartilage defects, recruits the body's progenitor cells to support repair — published outcomes of 81% good or excellent results, however, come from arthroscopic surgery, not the injection pathway used today.
Lincolnshire Hip Clinic
Led by Professor Paul Lee
Start with a free, non-medical discovery call with our team. We will tell you, honestly, which of our pathways — surgical or non-surgical — fits your situation. No GP referral, no pressure to proceed.
What we offer
